NCT03549468 (ELEVATE-ICM) is a NA clinical trial of Low level tragus stimulation in Ischemic Cardiomyopathy, sponsored by University of Oklahoma.

Who is sponsoring NCT03549468?

NCT03549468 is sponsored by University of Oklahoma.

What drugs are being tested in NCT03549468?

Interventions in NCT03549468: Low level tragus stimulation.

What condition does NCT03549468 study?

NCT03549468 studies Ischemic Cardiomyopathy.

Is NCT03549468 still recruiting?

NCT03549468 is currently completed. Last updated 26 May 2022.

Last reviewed 2022-05-26 · How we verify

NCT03549468: ELEVATE-ICM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Low LEVel TrAgus STimulation on the Electrophysiological Substrate of Patients With Ischemic CardioMyopathy Substrate of Subjects With Ischemic CardioMyopathy

Completed NA Last updated 26 May 2022

What this trial tests

NA trial testing Low level tragus stimulation in Ischemic Cardiomyopathy in 26 participants. Completed in 30 March 2022.

Timeline

25 May 2018

Primary endpoint
30 June 2021

30 March 2022

Quick facts

Lead sponsor	University of Oklahoma
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	26
Start date	25 May 2018
Primary completion	30 June 2021
Estimated completion	30 March 2022
Sites	1 location across United States

Drugs / interventions tested

Low level tragus stimulation

Conditions studied

Ischemic Cardiomyopathy — all drugs for Ischemic Cardiomyopathy →

Sponsor

University of Oklahoma

Who can join

Adults 18 to 90, any sex, with Ischemic Cardiomyopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with ischemic cardiomyopathy (left ventricular ejection fraction \<35%) and heart failure who already have an implantable device with an atrial lead (dual chamber defibrillator or biventricular defibrillator) will undergo sequentially 1. Sham low level tragus stimulation (LLTS) (5min), 2. Active LLTS at 5Hz (15min) and 20Hz (15min) and 3. Active LLTS group with atrial pacing at 100bpm at 5Hz (15min) and 20Hz (15min). The latter is required to examine the effect of LLTS on RA independent of heart rate. Repolarization alternans will be measured by analyzing a regular 12-lead ECG using a custom-made software.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Ischemic Cardiomyopathy

Currently open trials in the same condition.

NCT06930092 — RestoratIon of Myocardial Function by PeRcutaneous cOronary interVEntion in Patients With Ischemic CardioMyoPathy · NA · recruiting
NCT06661876 — Cardiac RadiothErapy For hEart faiLure · NA · recruiting
NCT05760924 — Left Bundle Branch Pacing on Outcomes and Ventricular Remodeling in Biventricular CRT Nonresponders · NA · recruiting
NCT06138873 — Ablation-Index Guided Scar-Mediated Ventricular Tachycardia Ablation in Patients With Ischemic Cardiomyopathy · NA · recruiting
NCT05632432 — Atrial Appendage Micrograft Transplants to Assist Heart Repair After Cardiac Surgery · NA · recruiting

Other University of Oklahoma trials

Trials by the same sponsor.

NCT07219706 — Dietary Fiber and Time Restricted Eating · NA · recruiting
NCT07494773 — Topical Methylene Blue-Photodynamic Therapy (MB-PDT) for Burn Wound Infection · Phase 1, PHASE2 · not yet recruiting
NCT07014605 — Smoking Cessation Program for Lao People With HIV · NA · not yet recruiting
NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07491653 — Fiber mHealth Intervention for Prediabetes · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03549468 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Oklahoma
Last refreshed: 26 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03549468.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing